Targenomix to continue its startup approach as a standalone entity wholly-owned by Bayer
Bayer has announced the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and computational life science tools to identify new modes of action for crop protection compounds.
The Targenomix expertise, personnel, and platforms will be an important part of delivering on Bayer’s commitment to the design of safe and effective molecules and will accelerate the discovery and development of molecules with the potential to make agricultural production more sustainable despite dynamic challenges like climate change, and increasing weed, disease and insect resistance.
Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery. Targenomix will continue its startup approach as a standalone entity wholly-owned by Bayer.
Dr Robert Reiter, Head of R&D at Bayer’s Crop Science Division said, “By using a unique and holistic systems biology approach and leveraging leading expertise building on a strong scientific foundation stemming from the MPI MPP, Targenomix has delivered numerous novel targets and modes of action for small molecules in weed control. Their innovative tools to identify and select safe and sustainable compounds complement our design-based strategy in crop protection discovery and will accelerate the development of new products that farmers need to meet future challenges of agriculture.”
By further integrating Targenomix’ systems biology approach into Bayer’s established R&D pipeline, Bayer is driving the development of innovative new technologies towards safe and effective products that farmers need. “Combining Bayer’s leading capabilities and proven crop protection pipeline with Targenomix’ flexible startup mindset, deep multi-omics technology, and systems biology expertise will allow us jointly to continue to deliver novel modes of action,” said Dr Sebastian Klie, CEO of Targenomix.